ENZOLYTICS INC - ENZC STOCK NEWS

Enzolytics, Inc. (OTC PINK: ENZC) announced progress on its business combination with Sagaliam Acquisition Corp. As part of the transition, Dr. Gaurav Chandra has been appointed CEO of Biogenysis. The deadline for completing the business combination has been extended to May 23, 2023, providing additional time for finalization. Enzolytics aims to leverage its AI and Monoclonal Antibody platforms in developing therapies for infectious diseases. CEO Charles Cotropia emphasized the commitment to advancing their technology pipeline, focusing on multiple Monoclonal Antibodies. The company continues to explore collaborations and aims for a strong intellectual property portfolio. Enzolytics has patented therapeutics targeting HIV/AIDS and other infectious diseases, including potential therapies for various viruses.

Enzolytics, Inc. (OTC PINK:ENZC) announced advancements in its ITV-1 immunotherapy for HIV treatment, with plans to deliver this therapy to hospitals in Africa. The treatment comprises two cycles of 16 injections over 17 weeks, with clinical data to be gathered post-treatment. ENZC has obtained a response from the European Medicines Agency regarding pharmacokinetics study standards. Additionally, studies conducted by the Bulgarian Academy of Science will aid in clinical trial validation. The company is finalizing a sale of Biogenysis and Virogentics to Sagaliam Acquisition Corp, with an anticipated dividend to ENZC shareholders upon regulatory approval. This transaction aims to provide necessary capital for continued development. ITV-1 has shown potential against multiple infectious diseases, although it remains unapproved by health regulatory bodies.

Enzolytics, Inc. (ENZC) has announced a non-binding term sheet with Sagaliam Acquisition Corp. (SAGA) for the sale of its subsidiaries, Biogenysis, Inc. (BGEN) and Virogentics, Inc. (VIRO), valued at $250 million. This agreement, expected to close on May 19, 2023, aims to provide BGEN and VIRO with necessary capital to fund ongoing clinical trials and marketing efforts, particularly for their anti-HIV treatment, ITV-1. The CEO of BGEN highlighted advancements in their AI platform, which plays a vital role in drug discovery. The press release mentions successful production of ITV-1 for distribution to African hospitals. It also notes Sagaliam's efforts to raise additional capital through a private investment in public equities that will further support the subsidiaries.

Enzolytics, Inc. (OTC PINK:ENZC) announced advancements in its monoclonal antibody program targeting Feline Leukemia Virus (FeLV). The company has filed a patent application covering over 26 conserved epitope sites identified through its artificial intelligence platform. These sites will facilitate the production of monoclonal antibodies, vaccines, and diagnostic tests. Notably, there are approximately 45 million cats in the U.S. impacted by FeLV, making this therapy potentially significant. Additionally, the company is in discussions with animal health providers and has initiated antibody production at Texas A&M University.

Enzolytics, Inc. (OTC PINK:ENZC) has successfully onboarded its IPF Immune™ nutritional supplement on Amazon, allowing direct sales through the platform. This move enables increased margins and promotional benefits. The product is expected to meet consumer demand in the $50 billion nutritional supplement market, with Amazon managing 37.8% of U.S. e-commerce. The company plans broad promotional strategies through its distributor, Nutritional Products International (NPI). NPI's recent hiring of sports nutrition expert Joseph Mies is expected to enhance market positioning. Enzolytics aims for significant success with IPF Immune, focusing on both U.S. and international markets.

Enzolytics, Inc. (OTC PINK:ENZC) has announced that its ITV-1 anti-HIV therapeutic has passed preliminary toxicology studies, confirming its non-toxic nature and safety for administration. This paves the way for potential regulatory approval in Africa, targeting countries with significant HIV populations, including Rwanda and DR Congo. The company estimates a revenue of over USD 45 million in the first year by treating 40,000-50,000 patients. Additionally, funding will be sought for further studies and product registrations in the EU and North America. Enzolytics aims to address the HIV pandemic significantly affecting Africa's populace.

Enzolytics, Inc. (OTC PINK:ENZC) has announced its initiative to develop fully feline monoclonal antibodies, leveraging its proprietary AI platform. Collaborating with Abveris, the company aims to create targeted antibodies for feline viruses, potentially accelerating market readiness compared to human-targeted therapies. With over 150 million cats in the U.S., this project addresses a significant market opportunity. Enzolytics has begun discussions with animal health providers interested in this innovation, building on its success in developing antibodies for SARS-CoV-2.

Enzolytics, Inc. (OTC PINK:ENZC) has completed its audits for financial years ending December 31, 2020, and December 31, 2021, with filings to support investor understanding of its operations. CEO Charles Cotropia highlighted advancements in clinical products and technology platforms, aiming for full SEC reporting. The company has launched its IPF Immune therapeutic, available online and through national retailers, with plans for international distribution. Enzolytics is focused on innovation in personalized medicine and has identified sites for Monkey Pox before WHO's public health emergency declaration.